Participated · Series B · Jun 2022

Frontier Field develops and provides 日病モバイル, a secure smartphone service for hospitals that supports staff calls and communications. The service includes integration with nurse call systems and electronic medical records to streamline workflows. Launched in 2020 to accelerate DX for physicians and nurses, the product aims to replace shrinking PHS usage and address upcoming 2024 working-hours reforms. 日病モバイル is positioned as a hub to connect medical systems, devices, and personnel rather than merely a PHS replacement. The service is currently used by about 60 hospitals and more than 20,000 healthcare workers. The company recently completed a Series C that includes debt financing and will use the proceeds to improve the convenience and value of 日病モバイル. フロンティア・フィールド operates “日病モバイル”, a secure smartphone and DX service built for hospitals that connects carrier switches to the company’s system via IP‑VPN and dedicated lines to protect patient data. The platform offers hospital-specific integrations and apps — including nurse‑call and electronic medical record linkage, emergency alerting, and multi‑vendor SIP/VoIP support — to simplify multi‑professional coordination while reducing personal data leakage risk. It is designed to replace PHS, paper, and fax workflows and to enable direct data entry in home‑visit care, eliminating double data entry. The company has deployed 日病モバイル in 19 hospitals as of March 2022 and, with Japan Hospital Association cooperation, targets about 40 hospitals by December 2022 and 300 hospitals / 60,000 lines by the end of 2024. The service emphasizes a closed network model to address hospitals’ sensitivity about Internet connectivity and offers a common authentication basis for multiple applications. The company was founded in July 2016 by Yasuyuki Sato, a former NTT Docomo and Japan Altmark executive.

Participated · Series B · Jan 2021

Metcela is a clinical-stage biotechnology company based in Kanagawa, Japan, developing first-in-class autologous cell therapies targeting serious cardiovascular diseases. Established in 2016, the company focuses on fibroblast and stem cell–based therapies for chronic diseases with limited treatment options. Metcela is advancing MTC001, a combination product of autologous cardiac cells (VCAM-1-positive Cardiac Fibroblast, VCF) paired with a novel catheter delivery system for chronic heart failure patients. The company recently closed a $14M Series C financing to support its plans. Proceeds will be used to prepare for commercialization by establishing manufacturing infrastructure, to strengthen new pipeline development capabilities, and to reinforce R&D by expanding research facilities. Metcela is positioning to move its clinical programs toward commercialization while expanding its research and manufacturing capacity. Metcela is a clinical-stage biotech founded in 2016 in Kanagawa, Japan, focused on developing fibroblast-based therapies for chronic diseases with limited options. Its lead asset, MTC001, is a VCAM-1-positive Cardiac Fibroblast (VCF) cell therapy that re-established a favorable microenvironment and repaired damaged heart tissues in preclinical studies. MTC001 uses a simple hospital-to-manufacturing-site-to-hospital workflow; VCF is collected from a cardiac biopsy in a minimally invasive manner. The company says VCF has significant manufacturing and safety advantages over alternative approaches. The $12.7M Series B enables Metcela to initiate Phase I clinical trials in Japan. Metcela intends to use the funds to grow its team and expand its portfolio. Metcela is a clinical-stage biotechnology company focused on developing fibroblast-based cell therapies. Its lead product, MTC001, is a fibroblast-based therapy intended to treat chronic heart failure. Through preclinical research the company identified VCAM-1-positive cardiac fibroblasts (VCFs) that stimulate cardiomyocyte proliferation and improve cardiac function via lymphangiogenesis. Metcela plans to accelerate clinical development of MTC001 and initiate a Phase I clinical trial. The company closed a ¥430m (≈$4m) Series B to support these efforts. Metcela is led by Co-CEOs Takahiro Iwamiya and Kenichi Nogami and recently appointed Kenji Yamada as an outside director.